Needham & Company Maintains Buy on Hyperion Therapeutics (HPTX) Post Q4
Tweet Send to a Friend
Needham & Company reiterated its Buy rating and $25 price target on Hyperion Therapeutics (NASDAQ: HPTX) following Q4 results.
This article: 143 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 143 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
